Zacks Investment Research on MSN
AC Immune (ACIU) upgraded to buy: Here's why
AC Immune (ACIU) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...
AC Immune (ACIU) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.21 per share a year ago. These figures are ...
The market expects AC Immune (ACIU) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2023. This widely-known consensus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results